A-share innovative drug concept stocks are active again, Sunshine Guojian Pharmaceutical rose over 10% to a new high, Yatai Pharm had two consecutive limit-ups, WECOME rose over 10%, and Baicheng Pharmaceutical, ALK, and Fushine followed suit

WECOME Pharmaceuticals released its performance for the first three quarters, with a net loss attributable to the parent company of 124 million yuan

According to the Zhitong Finance APP, WECOME released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 151 million yuan, a year-on-year decrease of 59.20%. The net loss attributable to shareholders of the listed company was 124 million yuan. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 122 million yuan. The basic loss per share was 0.8554 yuan

The A-share chain pharmacy IPO project is here: Kangbaijia starts counseling

Kangbaijia Pharmaceutical Group has initiated IPO counseling and plans to complete its listing in 2026. As a chain pharmacy with over 2,000 stores, Kangbaijia has a presence in Fujian, Zhejiang, Jiangxi, and other regions. Despite facing market pressures and regulatory challenges, Kangbaijia continues to expand its market share through acquisitions. After acquiring a subsidiary of WECOME in 2024, its market footprint extends into Zhejiang. Investment should be approached with caution, and market risks must be considered

The Zhejiang Securities Regulatory Bureau has issued warning letters to Minsheng Securities, Ren Shaozhong, and Zhong Desong

The Zhejiang Securities Regulatory Bureau has issued a warning letter to Minsheng Securities and its sponsoring representatives Ren Shaozhong and Zhong Desong. Minsheng Securities failed to adequately pay attention to the delays in construction projects and insufficient verification procedures during the continuous supervision of the initial public offering of Zhejiang WECOME, violating relevant management regulations

Innovative drug concept stocks continue to be active, HUAPONT LIFE SCIENCES hits the limit up

Innovative drug concept stocks continue to be active, HUAPONT LIFE SCIENCES hits the limit up, Shen Lian Biomedical, Staidson BioPharm, CISEN, and WECOME follow suit